Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings by Bartlett, John A. et al.
Lopinavir/ritonavir Monotherapy After Virologic Failure of First-
line Antiretroviral Therapy in Resource-limited Settings
John A. Bartletta,b, Heather J. Ribaudoc, Carole L. Wallisd, Evgenia Agac, David K.
Katzensteine, Wendy S. Stevensf, Michael R. Nortong, Karin L. Klingmanh, Mina C.
Hosseinipouri, John A. Crumpa,b, Khuanchai Supparatpinyoj, Sharlaa Badal-Faesenf,
Beatrice A. Kallungalk, and Nagalingeswaran Kumarasamyl
aDuke University Medical Center bKilimanjaro Christian Medical Centre cStatistical Data Analysis
Center, Harvard University dLancet Laboratories, South Africa eStanford University fUniversity of
Witswatersrand gAbbott hDivision of AIDS, National Institutes of Health iUniversity of North
Carolina- Chapel Hill and UNC Project, Lilongwe, Malawi jResearch Institute for Health Sciences,
Chiang Mai University kSocial and Scientific Systems lYRG Centre for AIDS Research and
Education.
Abstract
Objective—To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as
second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLS).
Design—Open-label pilot study of LPV/r monotherapy in participants on first-line non-
nucleoside reverse transcriptase inhibitor 3-drug combination ART with plasma HIV-1 RNA
1000–200 000 copies/mL.
Methods—Participants were recruited from 5 sites in Africa and Asia within the AIDS Clinical
Trials Group (ACTG) network. All participants received LPV/r 400/100mg twice daily. The
primary endpoint was remaining on LPV/r monotherapy without virologic failure (VF) at week
24. Participants with virologic failure were offered addition of emtricitabine and tenofovir (FTC/
TDF) to LPV/r.
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Results—Mutations associated with drug resistance were encountered in nearly all individuals
screened for the study. One hundred and twenty-three participants were enrolled, and 122
completed 24 weeks on study. A high proportion remained on LPV/r monotherapy without VF at
24 weeks (87%). Archived samples with HIV-1 RNA levels < 400 at week 24 (n = 102)
underwent ultrasensitive assay. Of these subjects, 62 had levels < 40 copies/mL and 30 had levels
40–200. Fifteen subjects experienced VF, among whom 11 had resistance assessed, and 2 had
emergent protease inhibitor mutations. The presence of baseline thymidine analogue mutations
and K65R predicted a lower VF rate. Thirteen subjects with VF added FTC/TDF, and 1 subject
added FTC/ TDF without VF. At study week 48, 11/14 adding FTC/TDF had HIV-1 RNA levels <
400 copies/mL.
Conclusions—In this pilot study conducted in diverse RLS, LPV/r monotherapy as second-line
ART demonstrated promising activity.
Introduction
More than five million HIV-1-infected persons are currently receiving antiretroviral therapy
(ART) globally [1], resulting in dramatic reductions of HIV-1-related morbidity and
mortality. The World Health Organization (WHO) recommends a simplified public health
approach to ART prescription to reach HIV-1-infected persons who live in resource-limited
settings (RLS) [2]. First-line ART is suggested with a non-nucleoside reverse transcriptase
inhibitor (NNRTI) and two nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs),
representing potent, safe and relatively inexpensive regimens. Virologic suppression rates on
first-line ART commonly exceed 80% at one year on treatment among patients who are
retained in care [3]. In the event of first-line ART failure, second-line ART is available in
many RLS, which consists of a boosted protease inhibitor (PI)- containing regimen in
combination with two NRTIs. Second-line ART also provides high rates of plasma HIV- 1
RNA suppression at 1 year, with approximately 75% of patients achieving levels < 400
copies/mL if they remain in care [3].
Despite the therapeutic successes of ART, considerable challenges remain. Monitoring of
plasma HIV-1 RNA levels is not available in most RLS, and as a result, first-line ART
failure is often identified by either immunological or clinical changes that may occur long
after loss of virologic suppression. The delay in identifying ART failure has been shown to
lead to the accumulation of complex resistance profiles that impact susceptibility to NRTIs
and their future use [4–8]. It is unknown to what extent the inclusion of NRTI in second-line
ART regimens contributes to antiretroviral activity given these observations. In the worst-
case scenario, NRTIs may only expose patients to the increased risk of drug-related
toxicities and add cost to second-line ART.
Previous studies of boosted PI monotherapy in treatment naïve HIV-1-infected persons have
suggested that most adherent patients can achieve significant virologic suppression, albeit
less robust than that achieved with 3 drug, multi-class drug combinations [9,10].
Interestingly, despite observations of low-level viremia among boosted PI monotherapy
recipients, studies to date have rarely identified the evolution of drug resistance mutations in
the HIV protease gene [11]. In RLS with limited availability of alternative antiretroviral
medications and extensive NRTI resistance following first-line virological failure, boosted
PI monotherapy could represent a viable option for second-line ART. The A5230 study of
the AIDS Clinical Trial Group (ACTG) was designed to evaluate the activity and tolerability
of second-line ART with lopinavir/ritonavir (LPV/r) monotherapy in a pilot study among
persons experiencing virologic failure on a first-line regimen containing an NNRTI and two
NRTIs. The study has a 24 week primary endpoint with continued long-term follow-up to 2
years; here we present the primary analysis results.
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ACTG A5230 is an open-label, multicenter pilot study of LPV/r monotherapy in subjects
failing a first-line regimen containing an NNRTI and two NRTIs, (NCT00357552). The
study was conducted at five Clinical Research Sites, including three sites in Africa
(Lilongwe, Malawi; Moshi, Tanzania; and Johannesburg, South Africa) and two sites in
Asia (Chiang Mai, Thailand; and Chennai, India). The primary objective of the study was to
demonstrate that LPV/r monotherapy provides at least a 65% virologic response rate in this
patient population, defined as achieving and maintaining HIV-1 RNA levels < 400 copies/
mL for at least 24 weeks while on LPV/r monotherapy.
Eligible subjects
Eligible subjects had documented HIV-1 infection with 2 methods of antibody and/or
antigen or nucleic acid detection, and were 18 years or older. They must have received a
first-line regimen containing an NNRTI and two NRTIs for at least 6 months continuously,
and have a plasma HIV RNA-1 level between 1000 and 200 000 copies/mL within 30 days
of study entry. Eligible subjects were also required to have the following laboratory values;
hemoglobin >8mg/dL, platelets >50 000/mm3, estimated creatinine clearance >60mL/
minute, AST, ALT and alkaline phosphatase <3 times the upper limit of normal, and total
bilirubin <2.5 times the upper limit of normal. Pregnant or breastfeeding women, and
persons with prior PI use, a serious medical condition within the previous 14 days, active
substance abuse, or evidence of chronic hepatitis B infection as documented by a positive
hepatitis B surface antigen result were excluded. All subjects provided written informed
consent.
Study evaluations
For the first 24 weeks following LPV/r treatment initiation, subjects returned at weeks 2 and
4, and then every 4 weeks until week 24. At every study visit a clinical assessment, list of
concomitant medications, adherence interview using the ACTG Adherence Questionnaire
[12] and pill count were performed. Serum chemistries, liver enzymes and hematology
values were measured at weeks 4, 8, 12 and 24. Fasting lipid panels were done at study
entry, and weeks 12 and 24. Plasma HIV-1 RNA levels were measured at study entry, and
weeks 12, 16, 20 and 24. CD4+ cell counts were measured at study entry, and weeks 16 and
24. All laboratories participated in international quality assurance testing. With the
exception of samples drawn at week 2 and 4, quantitation of HIV-1 RNA levels in A5230
was performed on-site in real time using a US Food and Drug Administration- approved
HIV-1 RNA assay; week 2 and 4 samples were tested at the time of the week 12 sample. In
a post-hoc analysis, all week 24 samples with plasma HIV RNA-1 <400 copies/mL
underwent further evaluation with the Abbott m2000rt RealTime™ assay, (Abbott
Laboratories, Abbott Park, Illinois USA; lower limit of detection 40 copies/mL) in one of
three designated laboratories. Samples for genotypic resistance testing were collected on all
subjects at the screening visit. Resistance testing was performed in-batch at two regional
laboratories using ViroSeq (Celera Diagnostics, CA) as per manufacturer’s instructions.
Briefly, a 1.7 kb amplicon was generated by a reverse transcriptase (RT)-initiated
polymerase chain reaction encompassing the entire protease (PR) and partial reverse
transcriptase (RT). Sequencing was performed with an ABI Prism 3100-Avant Genetic
Analyzer (Applied Biosystems, USA). HIV-1 subtype and drug resistance were determined
from PR and RT sequences, and analyzed using the Stanford Algorithm [13,14].
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All subjects received fixed dose combination (FDC) LPV/r 400 mg/100 mg twice daily. If
subjects developed virologic failure, FDC emtricitabine 200 mg/tenofovir 300 mg (FTC/
TDF) daily was added to LPV/r. Concomitant treatment with rifampin and other medications
listed in the LPV/r package insert was prohibited.
Primary endpoint
The primary endpoint was remaining on LPV/r monotherapy without virologic failure at
week 24. Virologic failure was defined as 1) failure to suppress plasma HIV-1 RNA to <400
copies/mL by week 24, or 2) confirmed rebound of plasma HIV-1 RNA levels to >400
copies/mL after confirmed suppression to <400 copies/mL. With some exceptions per
protocol, discontinuation of LPV/r monotherapy was considered as a primary endpoint;
exceptions included discontinuation for rifampin-based tuberculosis treatment, addition of
antiretroviral drugs due to pregnancy, and death with HIV-1 RNA levels <400 copies/mL.
Sample size
The target sample size of 120 subjects was chosen to provide at least 90% power to show
that LPV/r monotherapy could provide at least a 65% success rate over 24 weeks. This
assumed that the true success rate of the strategy in this population is 76%, and used a
onesided type I error rate of 5%.
Statistical analysis
Baseline characteristics of the study population were compared across sites using non-
parametric k-sample tests. The proportion of subjects remaining on LPV/r monotherapy
without virologic failure at week 24 was estimated with an exact 95% confidence interval.
The proportion of subjects with plasma HIV-1 RNA levels <400 copies/mL over time was
estimated using intent to treat methods with missing/off treatment evaluation ignored (M =
I) and considered as failure (>400 copies/ ml) (M = F); as treated analyses were also
performed. Exact logistic regression was used to assess factors associated with the
probability of failure; prior use of efavirenz (EFV) versus NVP, prior therapy duration (> 3
years, 1–3 years and <1 year), sex, baseline CD4+ cell count (<200 vs. >200/mm3), baseline
plasma HIV-1 RNA levels (<10 000 vs. >10 000 copies/mL), and NRTI resistance (defined
as K65R or thymidine analogue mutations (TAMs) vs. no NRTI resistance). In unplanned
post-hoc analyses, baseline HIV-1 RNA levels and rates of failure are described. All
analyses were restricted to data from study entry to the scheduled week 24 visit. In order to
provide information on the consequences of LPV/r monotherapy failure, the HIV- 1 RNA
and CD4+ cell count responses, and resistance findings through week 48 are included from
subjects reaching a primary failure endpoint.
Results
Baseline characteristics
One hundred twenty-three subjects entered the study; their baseline characteristics are
described in Table 1. The majority of subjects were female. The most common first-line
ART regimen was nevirapine, lamivudine (3TC) and stavudine (d4T)-containing regimens
(n = 63, 51%), and the majority of subjects had received ART for >3 years (n = 70, 57%).
The median plasma HIV-1 RNA level was 4.34 log10 copies/mL, and 21 subjects (17%) had
levels >100 000 copies/mL. The median CD4+ cell count at study entry was 164/mm3, and
70 subjects (57%) had counts <200/mm3. Screening plasma HIV-1 RNA levels, the
proportion of subjects with baseline CD4+cell counts below 100/mm3, and the proportion of
subjects meeting WHO CD4+ cell count criteria for regimen failure [15] were found to
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differ by site (P = 0.016, P<0.001, P = 0.002, P<0.001, respectively), with subjects from the
South African site having significantly lower values for each parameter.
Baseline resistance and subtyping
From the 114 screening samples that were successfully sequenced, nearly all subjects had
mutations associated with drug resistance. Most subjects were found to have mutations
associated with reduced susceptibility to 3TC (n = 108; 95%), EFV (n = 112; 98%) and
NVP (n = 112; 98%). Based on genotyping of the PR and partial RT, HIV-1 subtype C was
found to be the most prevalent (66%), followed by AE (19%), A1 (7%) and D (6%).
Subject disposition
Of 123 subjects who entered the study, 122 completed 24 weeks of study follow-up; one
subject died from a myocardial infarction deemed unrelated to treatment with a plasma
HIV-1 RNA level <400 copies/mL at week 20. All subjects remained on study treatment
(LPV/ r-monotherapy or LPV/r with FTC/TDF) throughout the 24-week primary endpoint.
Virologic responses
At week 24, 107 (87%) subjects remained on LPV/r monotherapy without virologic failure
(95% CI: 80- 92%). From week 16, >80% of subjects had plasma HIV- 1 RNA levels < 400
copies/mL regardless of how missing data and premature treatment discontinuations were
analyzed (Fig. 1). Of note, 95/102 subjects (93%) entering with baseline plasma HIV-1
RNA levels <100 000 copies/mL had achieved HIV-1 RNA <400 copies/mL by week 16
compared to 19/21 (90%) with baseline levels >100 000 copies/mL. One hundred and two
subjects had plasma HIV-1 RNA levels <400 copies/mL at week 24. Among these 102
subjects (panel within Fig. 1), 62 (61%) had plasma HIV-1 RNA <40 copies/mL, 30 (29%)
had levels 40–200 copies/mL, 7 (7%) had levels 201–400 copies/mL, and 3 (3%) had levels
>400 copies/mL, (respectively 413, 489 and 1712 copies/mL).
Virologic failures
Fifteen subjects met the criteria for virologic failure at week 24, and an additional subject
had FTC/TDF added without virologic failure (total failures 16, 13%), (Fig. 2). Failure
occurred in 6/21 subjects (29%) entering with baseline plasma HIV-1 RNA levels >100 000
copies/mL; in contrast, in the 102 subjects with baseline plasma HIV-1 RNA levels <100
000 copies/ml, 10 subjects (10%) met virologic failure criteria. Among the 15 subjects with
virologic failure, PR and RT sequences were obtained from 11 (73%); one individual had
insufficient sample available, and 3 samples could not be sequenced [HIV-1 RNA level
<1000 (2 subjects) and 1330 copies/mL (1 subject)]. PR mutations not observed at study
entry were identified in two subjects; V82F in one and L33F, M46I, I54V, V82A and L90M
in the second, (Table 2). With regard to NRTI-associated mutations at the time of virologic
failure, eight subjects had between 1 and 6 mutations that were no longer detectable
compared to mutations detected at screening. Five subjects gained one NRTI-associated
mutation from study entry to virologic failure. From study entry to virologic failure, no
NNRTI-associated mutations were gained by any of the subjects and in six subjects NNRTI
mutations were no longer detectable.
Predictors of virologic failure
In unadjusted and adjusted analyses, no associations between the potential predictors and
virologic failure were apparent (P>0.10).
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By study week 48, 14 (88%) of the 16 primary endpoint failures intensified their treatment
with FTC/TDF and 11 (79%) of 14 suppressed to <400 copies/mL following intensification
(Fig. 2). Among the three subjects who failed to suppress, one (33%) had newly emergent
PI-associated mutations at the time of virologic failure. Of the subjects who suppressed to
<400 copies/mL on treatment intensification, all were suppressed at study week 48. Table 2
lists the resistance profiles for subjects at screening and at virologic failure, categorized by
receipt of treatment intensification and virologic response. Among the 11 subjects who
suppressed HIV-1 RNA to <400 copies/mL, seven had at least one major NRTI-associated
resistance mutation that could no longer be detected by population-based sequencing.
Among the two subjects who did not suppress HIV-1 RNA levels to <400 copies/mL, both
either maintained the same number of NRTI-associated resistance mutations or gained a new
mutation.
CD4+ cell count responses
CD4+ cell counts increased from a median (Q1–Q3) of 164 (82–268)/mm3 at study entry to
a median of 268 (169–404)/mm3 at week 24. Among subjects remaining on LPV/r-
monotherapy without primary endpoint failure at week 24, the median CD4+ cell count
increase over 24 weeks was 102 cells/mm3 (46–157) compared to 111 (35–172) for the
primary endpoint failures.
Adherence
Adherence levels were generally high throughout the 24 weeks; by self-report, 79–90% of
subjects responded that they had never missed a dose of study medication at each adherence
assessment. Hypothesis-testing statistical analyses were not performed but there appeared to
be no differences in reported adherence between subjects who were virologic successes
versus failures.
Safety and tolerability
Thirty-one subjects (25%) experienced grade 3 or 4 adverse events during LPV/r
monotherapy (Table 3). The most common events included lipid elevations (1 subject with
grade 3 fasting triglycerides, 6 subjects with grade 4 fasting triglycerides, 5 subjects with
grade 3 fasting LDL cholesterol, and 5 subjects with grade 3 fasting total cholesterol),
elevations in fasting blood sugar (2 subjects with grade 3 and 4 subjects with grade 4), and
abnormalities in serum phosphorus (5 subjects with grade 3 hypophosphatemia).
Discussion
This pilot study, conducted at 5 geographic sites with multiple HIV-1 subtypes represented,
demonstrates promising antiretroviral activity of LPV/r monotherapy as second-line ART in
NNRTI-experienced HIV-infected persons. Over 24 weeks, 87% of subjects remained on
LPV/r monotherapy with plasma HIV-1 RNA levels suppressed to <400 copies/mL with the
lower limit on the estimated efficacy of the regimen of 80%, exceeding our target threshold
of 65%. Among subjects who developed virologic failure, treatment intensification with
FDC FTC/TDF resulted in suppression to <400 copies/mL over 48 weeks for the majority of
subjects.
As the number of HIV-1-infected persons on first-line ART grows, inevitably some will fail
and need second line ART. Currently the numbers of patients switching to second-line
regimens are relatively low, estimated at 3– 5% [16–18], although it is likely that 15–25% of
HIV-infected persons on first-line ART for at least 12 months have detectable plasma HIV-1
RNA [18]. When plasma HIV-1 RNA monitoring is available, it does lead to earlier
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switches to second-line ART [18], and better outcomes have been associated with RNA
<1000 copies/mL at the time of switching [19]. Unfortunately, in many RLS settings RNA
measurement is not available and first-line ART failure is recognized late, with the
consequence of increasing patient numbers with extensive NRTI and NNRTI resistance
mutations.
Other studies of second-line ART in RLS have demonstrated similar rates of virologic
suppression with use of LPV/r plus NRTI [19–21]. One study examined outcomes in 328
subjects receiving LPV/r, zidovudine and didanosine as second-line ART; plasma HIV-1
RNA levels were available for 262 subjects, and 203 (77%) had levels <400 copies/mL after
1 year, comparable to our results with LPV/r monotherapy [19]. Another study of second-
line ART in 141 South African subjects included the use of LPV/r and genotypic resistance
testing to guide the choice of the two NRTI’s [20]. Baseline characteristics of the South
African study population were similar to ACTG A5230 subjects with a median plasma
HIV-1 RNA of 17 000 copies/mL and 17% with RNA >100 000 copies/mL, although NRTI
and NNRTI resistance was not as extensive as observed in our population. Seventy-seven
percent of these subjects suppressed to <400 copies/mL and 65% to <50 copies/mL at week
24, similar to the 87% of subjects with <400 copies/mL and 50% (62/123) with <40 copies/
mL observed in ACTG 5230. A third study of second-line ART with LPV/r, zidovudine,
lamivudine and TDF among 109 persons in Malawi found that 85% of those surviving at
one year had plasma HIV-1 RNA levels <400 copies/mL [21].
Previous trials of LPV/r monotherapy have observed findings of low-level viremia in first-
line regimens, and randomized trials have demonstrated such viremia is significantly greater
with monotherapy compared to 3- drug LPV/r-containing regimens [9,10]. When week 24
samples for subjects remaining on LPV/r monotherapy with plasma HIV-1 RNA levels <400
copies/mL in A5230 were re-tested using an ultrasensitive assay, low-level viremia was
detected in 39% with the majority of samples measured in the 40–200 copies/mL range. The
significance of low-level viremia is uncertain, with other trials of LPV/r maintenance
monotherapy suggesting that it may remain stable for prolonged periods of time [22,23].
Numerous studies have demonstrated that resistance mutations in the protease gene are
infrequent in persons receiving boosted protease inhibitors [24], even as monotherapy,
despite this low-level viremia [11,23]. Similar observations were made in ACTG A5230-
only 7% (2/16) subjects virologically failing LPV/r monotherapy had protease mutations
that were not observed at study entry.
A recent Thai study randomized subjects failing first-line ART to either LPV/r monotherapy
or LPV/r, FTC and TDF, and was conducted simultaneously with ACTG A5230 [25]. They
observed that the proportion of subjects with viremia at levels 50–400 after 48 weeks was
significantly higher in the monotherapy arm (14% versus 3%), leading them to conclude that
3-drug second-line regimens were superior. A second randomized trial of LPV/r
maintenance monotherapy versus combination therapy (SARA trial) was conducted in
Uganda and Zimbabwe among 192 subjects who had received 24 weeks of second-line
combination therapy including LPV/r [26]. Plasma HIV-1 RNA was not monitored in real-
time, but testing of archived specimens revealed that the combination therapy group had
greater virologic suppression at week 24 (77% vs. 60% <50 copies/mL). Genotypic
resistance testing on 10 monotherapy subjects with plasma HIV-1 RNA levels >1000 copies/
mL revealed that a minority of subjects had new protease mutations at the time of failure.
Treatment intensification was not included in the SARA trial design, and the availability of
real-time plasma HIV-1 RNA monitoring and intensification represent an important
distinguishing feature of ACTG A5230.
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The short-term virologic responses to FTC/TDF intensification in ACTG A5230 subjects are
encouraging, and similar responses were observed in the Thai trial where 8/17 subjects in
the LPV/r monotherapy arm suppressed to <50 copies/mL following intensification with
FTC/TDF [25] and in trials of LPV/r monotherapy when NRTIs were added in subjects with
low-level viremia [23,24]. The strategy LPV/r monotherapy followed by treatment
intensification in the event of virologic failure may be critically important for future studies
of LPV/r monotherapy. However, this strategy does impose the need for plasma HIV-1 RNA
monitoring and associated costs that must be balanced against the high costs and potential
toxicities of second-line regimens which empirically include NRTIs [27]. An intriguing
association between reversion of NRTI resistance mutations detectable by population
sequencing at virologic failure and response to FTC/TDF intensification in ACTG A5230,
perhaps suggesting that some degree of re-sensitization may occur, although longer periods
of observation are needed to assess the durability of responses and the potential impact of
minor variants on longer-term outcomes. The continued follow-up of all subjects over 2
years on ACTG A5230 will provide more information on the durability of the strategy of
LPV/r monotherapy with intensification with FTC/TDF.
This study does have a number of limitations. It is a pilot, open-label uncontrolled study,
and the results must be cautiously interpreted. A larger randomized trial comparing second-
line ART with LPV/r monotherapy followed by FTC/TDF intensification for inadequate
responses versus 3-drug LPV/r-containing ART is warranted. Further, the more intensive
monitoring and support provided in a clinical trial may limit generalizing to responses in
clinical cohorts. Finally, at the present time we are only able to report results through the
primary endpoint follow-up to week 24; follow-up in ACTG A5230 is ongoing and will
continue until each subject has reached 104 weeks (expected in April 2012).
In summary, persons failing first-line ART with NNRTI-containing regimens have extensive
NRTI and NNRTI resistance mutations, which may carry important implications for second-
line ART choices. These pilot results suggest promising early responses to the strategy of
second-line LPV/r monotherapy, coupled with further virologic suppression following
intensification with FTC/TDF among persons with virologic failure.
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Table 1
Baseline characteristics.
Total (N = 123)
Age (yrs) Median (Q1, Q3)a 39 (33, 45)
Sex Female 70 (57%)






Total ARV exposure Median (Q1, Q3)a 3 (2, 4)
<1 years 9 (7%)
1 – <3 years 44 (36%)
3+ years 70 (57%)
HIV-1 RNA (log10 Median (Q1, Q3)a 4.34 (3.75, 4.92)
  (copies/mL)) < 3.00 4 (3%)
3.00–3.99 38 (31%)
4.00 – <4.99 60 (49%)
5.00 – <5.29 14 (11%)
5.3 7 (6%)
CD4 cell count Median (Q1, Q3)a 164 (82, 268)





Q1 and Q3 represent the 25th and 75th percentiles, respectively.
b
Prior regimen: most recent regimen before enrolling in A5230; Medication abbreviations: 3TC- lamivudine, EFV- efavirenz, TDF-tenofovir,
NVP- nevirapine, ZDV- zidovudine, D4T- stavudine, DDI- didanosine.






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Bartlett et al. Page 16
Table 3
Grade 3 or 4 adverse events during LPV/r monotherapy that were reported for at least 2% of the study
subjects.
Sign/Symptom/Laboratory Event Number of subjects by toxicity grade DAIDS Total number (%)
3 4 subjects
Total Triglycerides (fasting) 1 6 7 (6%)
Fasting Blood Sugar 2 4 6 (5%)
LDL (fasting) 5 0 5 (4%)
Phosphorus 5 0 5 (4%)
Total Cholesterol (fasting) 5 0 5 (4%)
SGOT 1 2 3 (2%)
Absolute Neutrophil Count 2 1 3 (2%)
Diarrhea/Loose Stools 2 1 3 (2%)
Total Bilirubin 2 1 3 (2%)
Hemoglobin 3 0 3 (2%)
SGPT 0 2 2 (2%)
Bicarbonate 1 1 2 (2%)
Potassium 1 1 2 (2%)
Cachexia/Wasting/weight Loss 2 0 2 (2%)
Table reflects the number of subjects reporting each category of symptom/lab event; 3 = Severe, 4 = Life-Threatening, 5 = Death. For each subject
the worst grade for each event category is reported.
AIDS. Author manuscript; available in PMC 2012 September 17.
